Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SpectRx makes progress with cervical cancer device:

This article was originally published in Clinica

Executive Summary

SpectRx says it has built and tested its first pre-production noninvasive cervical cancer detection device, which is to be used to complete the firm's ongoing US clinical trial necessary for regulatory approval. The beta device and single-patient-use disposables comprise major components planned for use in commercial production. The Norcross, Georgia company believes that the new-generation system will enable it to reach its price-of-production goals, making the technology affordable to physicians. The device, which uses proprietary technology to identify cancers and precancers painlessly by analysing light reflected from the cervix, is to be commercialised by SpectRx' subsidiary, Guided Therapeutics. SpectRx estimates the annual global market potential for a noninvasive cervical cancer test to be over $1.3bn.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel